The IDKmonitor® Infliximab Drug Level ELISA (Health Canada) is an enzyme immunoassay intended for the quantitative determination of free therapeutic TNFα antibodies infliximab (e.g., REMICADE®, Remsima®, Inflectra®) in EDTA plasma and serum.
Health Canada Licensed.
For Laboratory Professional Use Only.
Not for sale in the U.S. Please contact us to order or get a quote.
If you’re in the U.S., we offer an RUO version of this kit: KR9655
Manufactured by Immundiagnostik AG.
Also available:
This ELISA is designed to determine the quantity of free infliximab (therapeutic antibody against TNFα) in EDTA plasma or serum samples.
In the first incubation step, the free infliximab from the sample is bound to the specific monoclonal anti-infliximab antibody coated on the plate. A washing step is carried out to remove all unbound substances. In a further incubation step, a peroxidase-labeled antibody is added. Tetramethylbenzidine (TMB) is used as a substrate for peroxidase. Finally, an acidic stop solution is added to terminate the reaction.
The color changes from blue to yellow. The intensity of the yellow color is directly proportional to the concentration of free infliximab in the sample. Using the values obtained from the standard, a dose-response curve of the absorbance unit (optical density, OD) vs. concentration is generated. The concentrations of free infliximab in the samples are determined directly from this curve.
